1-3 of 3
Torsten Trowe
Close
Sort by
Journal Articles

A New Therapeutic Hypothesis: Nonsense-Mediated Decay Is an Exploitable Target in Multiple Myeloma

Alexander Leeksma, MD, Ingrid A.M. Derks, Brett Garrick, Torsten Trowe, Aldo Jongejan, PhD, Perry Moerland, PhD, Arnon P. Kater, MD, Eric Eldering, PhD, Ellen Filvaroff, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1937.
https://doi.org/10.1182/blood-2018-99-114801
Published: 2018
Journal Articles

A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001

Vincent Ribrag, MD, Julio C. Chavez, MD, Jason B Kaplan, MD, Umberto Vitolo, MD, Jason C. Chandler, MD, Armando Santoro, MD, Paolo Corradini, MD, Philippe Cassier, MD, Ian W. Flinn, MD PhD, Ranjana Advani, MD, Randeep Sangha, Iris Isufi, MD, Vaishalee P. Kenkre, MD, Patrick R. Hagner, Torsten Trowe, PhD, Anita K. Gandhi, PhD, Xiaoling Wu, PhD, Kristen Hege, MD, Michael Pourdehnad, John Kuruvilla, MD
Journal: Blood
Blood (2016) 128 (22): 1849.
https://doi.org/10.1182/blood.V128.22.1849.1849
Published: 2016
Journal Articles

Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia

Rachel Thijssen, Johanna ter Burg, Brett Garrick, Gregor G. W. van Bochove, Jennifer R. Brown, Stacey M. Fernandes, María Solé Rodríguez, Jean-Marie Michot, Michael Hallek, Barbara Eichhorst, Hans Christian Reinhardt, Johanna Bendell, Ingrid A. M. Derks, Roel J. W. van Kampen, Kristen Hege, Marie José Kersten, Torsten Trowe, Ellen H. Filvaroff, Eric Eldering, Arnon P. Kater
Journal: Blood
Blood (2016) 128 (4): 574–583.
https://doi.org/10.1182/blood-2016-02-700328
Published: 2016
Includes: Supplemental data